Migraine is a disorder characterized by moderate-to-severe throbbing pain episodes, usually unilateral in onset, aggravated by physical activity, with nausea, vomiting, photophobia, and phonophobia. Treatment of migraine includes both prophylactic treatment and acute treatment to end the attack. The American Academy of Neurology (AAN) and the American Headache Society (AHS) recently published guidelines for the prophylactic treatment of migraine; the guidelines for acute treatment were published by the AAN in 2000. A recent review published in Headche, authored by members of the AHS Guidelines Committee, updated the evidence on the acute phase pharmacotherapy of migraine from 1998-2013. The review included 132 pharmacotherapy studies that were classified as Class I-IV evidence based on the AAN Levels of Evidence. Grade U: Evidence for or against the use of the drug for acute migraine is controversial or insufficient. The review summarizes the current evidence for drug therapy as follows: Summary of key points: 1. The review reviews the efficacy of drugs for the acute treatment of migraine and gives the level of evidence for each drug, so that the evidence assessment can be used as a clinical guideline for drug use; 2. Based on the evidence from the review, the following classes of drugs are effective for the treatment of acute migraine: tretinoin, ergotamine derivatives, nonsteroidal anti-inflammatory drugs, opioids, and combination therapy drugs 3. In addition to the evidence of efficacy, clinicians should consider a combination of adverse effects, patient response, and drug interactions when prescribing. Therefore, drugs with Level A evidence of efficacy may not be first-line drugs; 4. No information is provided on the pharmacologic treatment of acute migraine in children and the elderly; 5. Only information is provided on the efficacy of each drug compared with placebo, and no information is provided on the efficacy of the two drugs compared with each other; 6.